MD vs THC vs NKTR vs AMSF vs HCA

For growth investors, HCA Healthcare, Inc.

(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Pediatrix Medical Group, Inc. (MD) offers the better valuation at 11. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Tenet Healthcare Corporation (THC) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pediatrix Medical Group, Inc.

(MD) is the cheapest at 11. 8x versus HCA Healthcare, Inc. at 15. 1x. On forward P/E, Pediatrix Medical Group, Inc. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.

4%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: THC returned +523. 4% versus MD's -67. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AMERISAFE, Inc.

(AMSF) is the lower-risk stock at 0. 23β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 700% more volatile than AMSF relative to the S&P 500. On balance sheet safety, AMERISAFE, Inc. (AMSF) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), HCA Healthcare, Inc.

(HCA) is pulling ahead at 7. 1% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, HCA leads at 7. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AMERISAFE, Inc.

(AMSF) is the more profitable company, earning 14. 9% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMSF leads at 18. 6% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pediatrix Medical Group, Inc. (MD) trades at 10. 3x forward P/E versus 14. 4x for AMERISAFE, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 59. 3% to $132. 83.

In this comparison, AMSF (8.

4% yield), HCA (0. 7% yield) pay a dividend. MD, THC, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, HCA Healthcare, Inc.

(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +450. 5%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MD (Healthcare) and THC (Healthcare) and NKTR (Healthcare) and AMSF (Financial Services) and HCA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MD is a small-cap deep-value stock; THC is a mid-cap deep-value stock; NKTR is a small-cap quality compounder stock; AMSF is a small-cap deep-value stock; HCA is a mid-cap deep-value stock. AMSF, HCA pay a dividend while MD, THC, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.